Huge Dental, a Chinese provider of dental materials, has renewed its application for an initial public offering (IPO) in Hong Kong. This move comes at a challenging time, as the market is flooded with listings from more prominent tech companies. The company’s recent financial performance has raised concerns, particularly with a 38% drop in profit and stagnant revenue, as highlighted in its latest listing documents.
The dental materials sector in China, where Huge Dental operates, is projected to grow significantly, with expectations of a 15% annual increase through 2029. Nevertheless, competition is intensifying, with numerous local entrants vying for market share. Once viewed as a sector with immense potential, the dental industry is now facing headwinds from a slowing economy and government initiatives aimed at controlling healthcare costs through centralized procurement.
Despite these challenges, Huge Dental’s listing has attracted attention due to a strong lineup of underwriters, including CICC, DBS, and Daiwa. This suggests that the IPO could raise significant funds, even though the company’s current market valuation is modest. Most peers in the sector are trading at price-to-earnings (P/E) ratios around 10, placing Huge Dental’s estimated value at approximately $100 million.
The dental materials market in China was valued at 30 billion yuan (approximately $4.4 billion) in 2024, with Huge Dental controlling about 1.3% of it. The company has reported that about two-thirds of its revenue comes from China, remaining stable at around 271 million yuan in both 2024 and 2025. Meanwhile, Europe accounts for 14% of its sales, and the United States, previously a significant market, saw revenue decrease by 42% last year, primarily due to tariffs and the loss of a major client.
As Huge Dental looks to expand globally, it has identified promising markets in Southeast Asia, India, and Europe. The company is also developing an offshore production base in Indonesia, which could enhance its competitive edge in these regions. Notably, the U.S. market is expected to remain challenging until tariff issues are resolved, and the company is considering the Middle East for future expansion.
The competitive landscape for dental companies in Hong Kong has become increasingly crowded. Recent IPOs, such as those of Meihao Medical, Arrail, and Dazhong Dental, have not performed well, with many seeing substantial declines in share prices since their listings. For instance, Dazhong and Meihao are down approximately 60%, while Arrail experienced an 87% drop before its shares were suspended in November following an audit dispute.
Despite the gloomy outlook for some of its peers, Huge Dental’s story may offer a glimmer of hope. The company reported a steady gross margin of around 58% over the past three years. However, rising marketing and administrative expenses have raised concerns, as profit fell to 47.7 million yuan in the previous year from 76.6 million yuan in 2024.
Overall, Huge Dental’s IPO represents a complex picture of opportunity and risk. The company faces significant challenges in its domestic market due to economic pressures and fierce competition. However, its strategic focus on international markets may provide avenues for growth and recovery. Attracting investor interest will be crucial in a market primarily focused on high-tech offerings, and Huge Dental must work diligently to carve out its niche as it prepares for its Hong Kong debut.
